214 related articles for article (PubMed ID: 36248903)
1. Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.
Ghorbanalipoor S; Emtenani S; Parker M; Kamaguchi M; Osterloh C; Pigors M; Gross N; Khil'chenko S; Kasprick A; Patzelt S; Wortmann D; Ibrahim IO; Izumi K; Goletz S; Boch K; Kalies K; Bieber K; Smith P; Schmidt E; Ludwig RJ
Front Immunol; 2022; 13():865241. PubMed ID: 36248903
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita.
Gross N; Marketon J; Mousavi S; Kalies K; Ludwig RJ; Bieber K
Front Immunol; 2024; 15():1343299. PubMed ID: 38799441
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita.
Koga H; Kasprick A; López R; Aulí M; Pont M; Godessart N; Zillikens D; Bieber K; Ludwig RJ; Balagué C
Front Immunol; 2018; 9():1558. PubMed ID: 30050528
[TBL] [Abstract][Full Text] [Related]
4. Epidermolysis bullosa acquisita with combined features of bullous pemphigoid and cicatricial pemphigoid.
Wieme N; Lambert J; Moerman M; Geerts ML; Temmerman L; Naeyaert JM
Dermatology; 1999; 198(3):310-3. PubMed ID: 10393462
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid.
Shimanovich I; Mihai S; Oostingh GJ; Ilenchuk TT; Bröcker EB; Opdenakker G; Zillikens D; Sitaru C
J Pathol; 2004 Dec; 204(5):519-27. PubMed ID: 15538734
[TBL] [Abstract][Full Text] [Related]
6. Fcγ Receptor IIB Controls Skin Inflammation in an Active Model of Epidermolysis Bullosa Acquisita.
Kovacs B; Tillmann J; Freund LC; Nimmerjahn F; Sadik CD; Bieber K; Ludwig RJ; Karsten CM; Köhl J
Front Immunol; 2019; 10():3012. PubMed ID: 31993051
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita.
Haeger SC; Kridin K; Pieper M; Griewahn L; Nimmerjahn F; Zillikens D; König P; Ludwig RJ; Hundt JE
Front Immunol; 2022; 13():938306. PubMed ID: 36311755
[TBL] [Abstract][Full Text] [Related]
8. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita).
Ujiie H; Iwata H; Yamagami J; Nakama T; Aoyama Y; Ikeda S; Ishii N; Iwatsuki K; Kurosawa M; Sawamura D; Tanikawa A; Tsuruta D; Nishie W; Fujimoto W; Amagai M; Shimizu H;
J Dermatol; 2019 Dec; 46(12):1102-1135. PubMed ID: 31646663
[TBL] [Abstract][Full Text] [Related]
9. PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita.
Koga H; Recke A; Vidarsson G; Pas HH; Jonkman MF; Hashimoto T; Kasprick A; Ghorbanalipoor S; Tenor H; Zillikens D; Ludwig RJ
J Invest Dermatol; 2016 Nov; 136(11):2211-2220. PubMed ID: 27388992
[TBL] [Abstract][Full Text] [Related]
10. A practical technique for differentiation of subepidermal bullous diseases: localization of in vivo-bound IgG by laser scanning confocal microscopy.
Wozniak K; Kazama T; Kowalewski C
Arch Dermatol; 2003 Aug; 139(8):1007-11. PubMed ID: 12925388
[TBL] [Abstract][Full Text] [Related]
11. Studies on complement deposits in epidermolysis bullosa acquisita and bullous pemphigoid.
Mooney E; Falk RJ; Gammon WR
Arch Dermatol; 1992 Jan; 128(1):58-60. PubMed ID: 1371212
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease.
Hashimoto T; Ishii N; Ohata C; Furumura M
J Pathol; 2012 Sep; 228(1):1-7. PubMed ID: 22692770
[TBL] [Abstract][Full Text] [Related]
13. Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: demonstration by leukocytic attachment and organ culture methods.
Gammon WR; Inman AO; Wheeler CE
J Invest Dermatol; 1984 Jul; 83(1):57-61. PubMed ID: 6376640
[TBL] [Abstract][Full Text] [Related]
14. The Immunometabolomic Interface Receptor Hydroxycarboxylic Acid Receptor 2 Mediates the Therapeutic Effects of Dimethyl Fumarate in Autoantibody-Induced Skin Inflammation.
Wannick M; Assmann JC; Vielhauer JF; Offermanns S; Zillikens D; Sadik CD; Schwaninger M
Front Immunol; 2018; 9():1890. PubMed ID: 30154797
[TBL] [Abstract][Full Text] [Related]
15. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita.
Kirtschig G; Murrell D; Wojnarowska F; Khumalo N
Cochrane Database Syst Rev; 2003; 2003(1):CD004056. PubMed ID: 12535507
[TBL] [Abstract][Full Text] [Related]
16. Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita.
Samavedam UK; Mitschker N; Kasprick A; Bieber K; Schmidt E; Laskay T; Recke A; Goletz S; Vidarsson G; Schulze FS; Armbrust M; Schulze Dieckhoff K; Pas HH; Jonkman MF; Kalies K; Zillikens D; Gupta Y; Ibrahim SM; Ludwig RJ
Front Immunol; 2018; 9():249. PubMed ID: 29497423
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-related proteins-8 and -14 are expressed but dispensable in the pathogenesis of experimental epidermolysis bullosa acquisita and bullous pemphigoid.
Akbarzadeh R; Yu X; Vogl T; Ludwig RJ; Schmidt E; Zillikens D; Petersen F
J Dermatol Sci; 2016 Mar; 81(3):165-72. PubMed ID: 26692467
[TBL] [Abstract][Full Text] [Related]
18. Epidermolysis bullosa acquisita: what's new?
Ishii N; Hamada T; Dainichi T; Karashima T; Nakama T; Yasumoto S; Zillikens D; Hashimoto T
J Dermatol; 2010 Mar; 37(3):220-30. PubMed ID: 20507385
[TBL] [Abstract][Full Text] [Related]
19. Epidermolysis bullosa: variability of expression of cicatricial pemphigoid, bullous pemphigoid, and epidermolysis bullosa acquisita antigens in clinically uninvolved skin.
Fine JD
J Invest Dermatol; 1985 Jul; 85(1):47-9. PubMed ID: 3891876
[TBL] [Abstract][Full Text] [Related]
20. Acquired bullous diseases of childhood: re-evaluation of diagnosis by indirect immunofluorescence examination on 1 M NaCl split skin and immunoblotting.
Kirtschig G; Wojnarowska F; Marsden RA; Edwards S; Bhogal B; Black MM
Br J Dermatol; 1994 May; 130(5):610-6. PubMed ID: 8204469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
